Physician profile
Sherry Rivera
NPI 1982188421
$2,201.90
in general payments reported to CMS, 2019-2025
22 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $405 · 2022: $427 · 2023: $639 · 2024: $617 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,368.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $367.13 | 2021-2024 | Farxiga, Airsupra, Lokelma |
| Lilly USA, LLC | $280.55 | 2021-2024 | Mounjaro |
| Merck Sharp & Dohme LLC | $226.35 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Astellas Pharma US INC | $175.67 | 2021-2023 | Veozah |
| Novo Nordisk INC | $155.40 | 2021-2024 | Ozempic, Rybelsus, Saxenda |
| Pfizer INC. | $150.39 | 2021-2025 | |
| Abbvie INC. | $138.11 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.77 | 2021-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $107.90 | 2021-2024 | Eliquis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $98.77 | 2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $65.46 | 2023-2024 | Nuedexta, Rexulti |
| Ibsa Pharma INC. | $52.34 | 2023-2024 | Licart, Tirosint, Tirosint |
| Shield Therapeutics INC | $42.22 | 2023 | Accrufer |
| Phathom Pharmaceuticals, INC. | $36.66 | 2024 | Voquezna |
| Abbott Laboratories | $36.56 | 2024-2025 | Freestyle Libre 3 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $27.46 | 2023 | Repatha |
| Novartis Pharmaceuticals Corporation | $21.46 | 2023 | |
| Avanir Pharmaceuticals, INC. | $19.80 | 2022 | |
| Medtronic, INC. | $19.04 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.77 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.71 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherry Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.